VISTA Blocking KVA12123 Monoclonal Antibody (mAb) Engineered to Provide Strong Single Agent Anti-Tumor Activity While Minimizing Cytokine Related Adverse Events...
Health Care Service Corporation, Laerdal Million Lives Fund, BayCare, Parkview Health, University of Chicago Medicine, Organon and Stryker to support...
Long term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new...
Long term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new...
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 12, 2023 –...
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence"...
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence"...
Stage II completed; comprehensive results expected in Q1 2024; company's planned regulatory pathway for FDA approval remains on trackCancer patients...
VANCOUVER, BC / ACCESSWIRE / December 11, 2023 / WEX Pharmaceuticals Inc. ("WEX" or the "Company"), a biotechnology company developing...
Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11,...
Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory...
Agreement Expands Partnership Between Cosmo Pharmaceuticals and Medtronic, Set to Transform Endoscopy with Cutting-Edge AI Technology Ad hoc announcement pursuant...
USE OF PARSORTIX SYSTEM IN PRE-CLINICAL MODEL UNLOCKS OPPORTUNITIES FOR DRUG DISCOVERYHarvested CTCs reveal gene expression profile associated with development...
POLB 001 - targeting Cytokine Release Syndrome (CRS) associated with cancer immunotherapiesLONDON, UK / ACCESSWIRE / December 11, 2023 /...
Reporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML PatientsTUS Single...
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesAt...
A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion...
Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1...
Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer careNew data demonstrates MRD...
CHICAGO, IL / ACCESSWIRE / December 8, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...